Company
Intercept Pharmaceuticals
Intercept Pharmaceuticals has 7 drugs tracked on RxWires: 1 post-market, 1 in Phase 3, 1 in Phase 2/3, 3 in Phase 2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Obeticholic Acid (OCA) | Post-Market | Liver Cirrhosis, Biliary |
| FDC tablet (OCA 5 mg + BZF 400 mg SR) | Phase 3 | Primary Biliary Cholangitis |
| OCA | Phase 2/3 | Biliary Atresia |
| Bezafibrate 100 mg | Phase 2 | Primary Biliary Cholangitis |
| INT-747 | Phase 2 | Diabetes Mellitus, Type II |
| INT-787 | Phase 2 | Alcohol Associated Hepatitis |
| Ocaliva | Not Applicable | Healthy |
Latest
No recent events.
Follow Intercept Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.